Crucial Innovations Corp. Unveils 4TP, Enhancing Patient Access to Medicinal Cannabis

LONDON, January 21, 2026 — Crucial Innovations Corp. (OTC: CINV), a leading pharmaceutical biotechnology company focused on advancing high-quality cannabis-based products for medicinal use, today announced the launch of 4TP, a new patient-oriented brand developed to support clinicians and patients in the UK and Europe.

What Is 4TP?

4TP, an acronym for “For The People,” represents Crucial Innovations Corp.’s commitment to delivering carefully cultivated, consistent, and scientifically supported cannabis-based medicines — known as CBPMs (Cannabis-Based Products for Medicinal Use).

The new brand is built around the company’s “Plant-to-Patient” operating model, which integrates regulated cultivation, pharmaceutical-grade processing, and clinician-led access into a single, transparent value chain for medical cannabis supply and distribution.

Bridging Science and Patient Care

4TP aims to connect plant science with practical patient care by combining disciplined cannabis cultivation with structured educational materials tailored for prescribers and patients. These resources are designed to support informed decision-making and strengthen communication between healthcare professionals and those they treat.

This includes comprehensive explanations of terpenes, cultivar characteristics, cultivation processes, and other factors that influence therapeutic outcomes — all aligned with clinical workflows and regulatory standards.

Supporting Consistency and Transparency

Every 4TP product is developed in audited, Standard Operating Procedure (SOP)-driven environments. Experienced teams prioritize terpene expression, batch consistency, and documented control over every stage of production.

By maintaining traceability and rigorous quality systems, the company hopes to strengthen clinician confidence and offer patients clearer insight into how their medicinal products are grown, processed, and governed — a level of transparency that is often lacking in legacy or purely consumer-oriented cannabis brands.

CEO Statement on the 4TP Launch

“When patients and clinicians understand how a medicine is developed and governed, trust follows,” said JP Doran, CEO of Crucial Innovations Corp. “4TP embodies our Plant-to-Patient philosophy, bringing together regulated cultivation, pharmaceutical processing and clinician-led access into a single, auditable framework. This is about moving medical cannabis firmly into the language and discipline of modern healthcare.”

Advancing Medical Cannabis Through Quality and Governance

With the launch of 4TP, Crucial Innovations Corp. seeks to deepen confidence across clinics, pharmacies, and prescribing networks by reinforcing pharmaceutical logic, quality systems, and clear educational support. The brand emphasizes consistency, safety, and accountability — fundamental principles for broader adoption of medical cannabis treatments.

The introduction of 4TP also marks another milestone in CINV’s strategy to build scalable, regulator-ready medical platforms that can be replicated in other jurisdictions without major changes to core processes. The company believes this approach demonstrates operational repeatability, capital efficiency, and a long-term commitment to advancing cannabis-based medicine.

About Crucial Innovations Corp.

Crucial Innovations Corp. (OTC: CINV) is a pioneering pharmaceutical biotechnology platform focused on cultivating and distributing high-quality cannabis-based products for medicinal use across the UK and Europe. Through a vertically integrated “seed-to-patient” supply chain, the company aims to set new standards in consistency, safety, and accessibility of therapeutic cannabis.

For more information, visit the company’s official website at www.cinvcorp.com.

#4TP #CrucialInnovations #MedicalCannabis #PlantToPatient #SlimScan #GrowthStocks #CANSLIM